Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Glenmark Pharmaceuticals Limited
Press Release Mar 04 2026
Business
Mar 4 2026
5 min read

Press Release Mar 04 2026

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 04, 2026, titled "Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity".

View Attachment